OXFORD, United Kingdom--(BUSINESS WIRE)--Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), today announced the filing of a Marketing Authorisation Application (MAA) for lubiprostone in the United Kingdom. The MAA is for lubiprostone, 24 mcg, for the indication of Chronic Idiopathic Constipation in adults. Lubiprostone was previously developed by Sucampo Pharmaceuticals, Inc. for the treatment of chronic idiopathic constipation in adults in the United States.
